Evidence map›Paper›PMID 21228923›Full record

ArticleInternational journal of clinical and experimental pathology2010

Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

David V Gold, Rhona Stein, Jack Burton, David M Goldenberg

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins.International journal of molecular sciences · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David V GoldGarden State Cancer Center, Center for Molecular Medicine and Immunology Belleville, NJ 07109, USA. dvgold@gscancer.org
Rhona Stein
Jack Burton
David M Goldenberg

Funding

Detection and Diagnosis of Pancreatic CarcinomaR01CA096924 · NCI · CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY · PI GOLD, DAVID V · 2005 to 2014
$2.3M
NCI NIH HHS R01 CA096924
6 · The paper itself

Abstract

CD74, a transmembrane glycoprotein that associates with MHC II, is an important chaperone that regulates antigen presentation for immune response. In addition, CD74 is the receptor for macrophage migration-inhibitory factor which, when bound to CD74, initiates survival pathways and cell proliferation. Formalin fixed, paraffin embedded clinical specimens were evaluated by immunohistochemical procedures for expression of CD74. Overall, expression of CD74 within gastrointestinal carcinomas showed a statistically greater expression than in the normal tissue counterparts (P<0.001 or better). CD74 expression was observed in 95% of pancreatic carcinomas with the majority of cases presenting a mostly intense, diffuse labeling pattern. The results suggested a trend towards greater expression within the higher grade carcinomas (P=0.06). Colorectal and gastric carcinomas gave similar results with 60% and 86%, respectively, positive for CD74 with an intense, diffuse staining pattern. We hypothesized that precursor lesions would express levels of CD74 as high, or higher, than their respective carcinomas, since activation of survival pathways would be of particular importance at the early stages of neoplastic development. For PanIN lesions there was greater expression of CD74 within higher grade, PanIN-3 lesions, whereas the colonic adenomas showed no such trend, but overall, a higher frequency and intensity of CD74 labeling than was observed within the colon carcinomas. These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.

Indexed as

AdenocarcinomaAdenomaAntigens, Differentiation, B-LymphocyteBiomarkers, TumorColorectal NeoplasmsDigestive System NeoplasmsHistocompatibility Antigens Class IIHumansImmunohistochemistryPancreatic NeoplasmsStomach NeoplasmsTissue Array AnalysisAntigens, Differentiation, B-LymphocyteBiomarkers, TumorHistocompatibility Antigens Class IIinvariant chainCD74colon carcinomagastric carcinomainvariant chainpancreatic carcinoma

Identifiers

PMID21228923
PMCPMC3016099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.